The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Colchicine: An Ancient Drug with Modern Uses

Colchicine: An Ancient Drug with Modern Uses

August 11, 2021 • By Ibrahem Salloum, MD, & Deepan S. Dalal, MD, MPH

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Discovered more than 3,000 years ago, colchicine is one of the oldest drugs still in use today. Like most old remedies, colchicine is a chemical substance found in many plants, most notably in colchicum autumnale, known as wild saffron or autumn crocus. It was mentioned in the oldest Egyptian medical text, Ebers Papyrus (circa 1550 B.C.), where it was described for the use of pain and swelling.1

You Might Also Like
  • FDA Enforcement Against Injectable Colchicine
  • Generic Colchicine Approved for Gout Prophylaxis
  • FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare
Explore This Issue
September 2021

As early as the 1st century A.D., Pedanius Dioscorides, a Greek physician and pharmacologist, describes the use of colchicum to treat gout in his pharmacopeia, De Materia Medica.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Colchicine’s name may come from its use as a poison in the district of Colchis of ancient Greek. Medea, the sorceress daughter of the king of Colchis, used it as one of her poisons, and it was referred to in Greek mythology as “the destructive fire of the Colchicon Medea.”1,2

Over the course of years, the drug has been described in various texts from Persia and Turkey, and it was noted in the London Pharmacopeia in 1618.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the 18th century, a French military officer, Nicolas Husson, used colchicine as the main ingredient in Eau Medicinale, a product he developed as a commercial remedy to treat gout. Benjamin Franklin used this product successfully to treat his own gout and is credited with introducing colchicine to the U.S.1

Colchicine was first isolated in 1820 by French chemists Pierre-Joseph Pelletier and Joseph-Bienaimé Caventou, and a purified active ingredient named colchicine was developed in 1833 by Philipp Lorenz Geiger.3

Despite colchicine’s long history of use, it was not until 2009 that the U.S. Food & Drug Administration approved colchicine to treat gout and familial Mediterranean fever (FMF) under the Unapproved Drugs Initiative.4 Beyond gout and FMF, colchicine is widely used to treat a variety of dermatologic conditions, and its role is being investigated for the treatment of coronary artery disease and even COVID-19 infection.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Mechanism of Action

Colchicine binds to tubulins, blocking the assembly, polymerization and—at higher concentrations—depolymerization of microtubules. Colchicine has multiple effects on the function of the immune system. It inhibits neutrophils’ chemotaxis, adhesion, mobilization and superoxide anion production. It also inhibits the NLRP3 inflammasome complex that mediates interleukin 1β activation. Because it binds to tubulin, colchicine interferes with mitosis.

Despite its antimitotic effect, the efficacy of colchicine in curbing the inflammatory process without prohibiting toxicities may be due to its tendency to highly concentrate in the neutrophils, possibly related to their low expression of ABCB1 drug transporter gene.5,6

Pages: 1 2 3 4 5 6 7 | Single Page

Filed Under: Drug Updates Tagged With: anti­inflammatory, Colchicine, drug treatment, Gout, Gout Resource Center, inflammationIssue: September 2021

You Might Also Like:
  • FDA Enforcement Against Injectable Colchicine
  • Generic Colchicine Approved for Gout Prophylaxis
  • FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare
  • Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)